{"id":"W2938589827","doi":"10.1016/s1470-2045(19)30082-8","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":813,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Research and Development","keywords":"Abiraterone acetate; Prostate cancer; Medicine; Prednisone; Internal medicine; Oncology; Androgen deprivation therapy; Urology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06476036434540433,"score_gpt":0.3773706945959527,"score_spread":0.3126103302505484,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}